A Study to Evaluate the Irritation Potential of ATx201 in Healthy Volunteers

UNION Therapeutics

Status and phase: Completed; Phase 1

Conditions: Irritation Potential of Topic Agent

Treatments: Drug: ATx201 Gel 4%; Drug: ATx201 Placebo; Drug: Negative Control; Drug: Positive Control; Drug: ATx201 Gel 2%

Study type: Interventional

Funder types: Industry

Identifiers

NCT03301870

ATx201-006

Details and patient eligibility

About

This is a Phase I single-site study to evaluate the irritation potential of topically applied ATx201 GEL, 2% and 4%, along with positive and negative control and placebo control (ATx201 GEL Placebo), in healthy human subjects on intact and abraded skin. Approximately thirty-six (36) healthy adult subjects will receive all the test articles to provide for 30 subjects to complete the study. The test articles will be applied to the upper back of the subjects during the study, and the placement of the test articles will be randomized. Abraded skin will be induced using sequential tape stripping.

Enrollment: 36 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Judged by the Investigator to have no health conditions that would impact the safety of the subject during participation.
• Body Mass Index (BMI) to be no less than 19.0 and no greater than 36.0 kg/m² (inclusive).
• Demonstrates a Fitzpatrick skin score of I - IV
• Female subjects must agree to use a medically acceptable contraceptive method
• Willing to refrain from excessive consumption of sodium (> 2,400 mg/day or > 1 teaspoon equivalent/day) in food or beverage 48 hours prior to Day 1 through EOS Visit.
• Willing to shower using the same non-medicated soap/cleansers, and abstain from excessive sun exposure (including tanning salons) from the Screening Visit through EOS Visit.

Exclusion criteria

• any clinical investigational product within 30 days prior to Day 1 through EOS Visit
• recent or current medical condition that, in the opinion of the Investigator, might significantly affect an immunological response to topical ATx201 or compromise the safety of the subject.
• history of diabetes mellitus, clinically significant asthma (acceptable if no episode within 5 years prior to Day 1), or currently diagnosed with hypertension or circulatory disease.
• use of any medication on a regular basis within 14 days prior to Day 1 through EOS that could change peripheral blood flow, with the exception of any prescribed birth control method or hormone replacement therapy.
• use of any oral, nasal or topical corticosteroids, or oral or topical retinoids (other than Vitamin A at normal dietary amounts) within 14 days prior to the Screening Visit through EOS Visit.
• intending to start, stop, or change the dose of any prescription or over-the-counter (OTC) medication within 48 hours prior to Day 1 through EOS Visit.
• use of any prescription or OTC topical medications on the upper back within 30 days prior to Day 1 through EOS Visit.
• history of sensitivity/allergy to any ingredients found in the ATx201 formulation or has a history of adverse reactions to topical medications.
• significant history of allergy to soaps, lotions, emollients, ointments, creams, cosmetics, adhesives, or latex.
• history of significant skin conditions or disorders such as psoriasis, atopic dermatitis, etc.
• history of significant dermatologic cancers, for example, melanoma or squamous cell carcinoma.
• displays an obvious difference in skin color on the upper back or the presence of a skin anomaly such as a recent sunburn, scratch, scar tissue, tattoo, or coloration that would interfere with placement of test sites, their assessment, and their potential response to the study drug or that could compromise the safety of the subject.
• smoking or use of tobacco or nicotine delivery products within 14 days prior to Day 1 through EOS Visit.
• female who is pregnant, lactating, breastfeeding, or intends to become pregnant over the course of the study.
• history of drug or alcohol addiction or abuse within the past year.
• caffeine intake greater than 500 mg per day (for example, 1 cup of coffee contains approximately 85 mg of caffeine, tea approximately 25 mg, soft drinks up to 115 mg, energy drinks 90 - 422 mg).
• unwilling to abstain from energy drinks, alcohol, and excessive caffeine (> 500 mg/day) for 48 hours prior to Day 1 through EOS Visit.
• reports having donated blood or plasma within 48 hours prior to Day 1 through EOS Visit.

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

36 participants in 9 patient groups, including a placebo group

ATx201 GEL, 2% - intact skin

Experimental group

Description:

ATx201 GEL, 2% applied intact skin

Treatment:

Drug: ATx201 Gel 2%

ATx201 GEL, 4% - intact skin

Experimental group

Description:

ATx201 GEL, 4% applied to intact skin

Treatment:

Drug: ATx201 Gel 4%

ATx201 GEL, 2% - abraded skin

Experimental group

Description:

ATx201 GEL, 2% applied to abraded skin

Treatment:

Drug: ATx201 Gel 2%

ATx201 GEL, 4% - abraded skin

Experimental group

Description:

ATx201 GEL, 4% applied to abraded skin

Treatment:

Drug: ATx201 Gel 4%

ATx201 GEL Placebo - intact skin

Placebo Comparator group

Description:

ATx201 GEL Placebo applied to intact skin

Treatment:

Drug: ATx201 Placebo

ATx201 GEL Placebo - abraded skin

Placebo Comparator group

Description:

ATx201 GEL Placebo applied to abraded skin

Treatment:

Drug: ATx201 Placebo

Negative Irritant Control - intact skin

Active Comparator group

Description:

Negative (low) Irritant Control applied to intact skin

Treatment:

Drug: Negative Control

Negative Irritant Control - abraded skin

Active Comparator group

Description:

Negative (low) Irritant Control applied to abraded skin

Treatment:

Drug: Negative Control

Positive Irritant Control - intact skin

Active Comparator group

Description:

Positive (high) Irritant Control applied to intact skin

Treatment:

Drug: Positive Control